个人中心 - 老虎社区

ZenS

IP属地：未知

帖子 · 2帖子 · 2
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- ZenSZenS
  ·2021-12-07
  [Happy] [Happy]
  4 of the Safest Dividend Stocks That'll Help You Crush Inflation
  Apple and four other tech stalwarts are well insulated from inflation.
  4 of the Safest Dividend Stocks That'll Help You Crush Inflation
  1,563 评论
  点赞
  分享
  举报
- ZenSZenS
  ·2021-12-02
  Both
  Moderna or Pfizer Stock: Which to Buy as Omicron Spreads?
  Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks
  Moderna or Pfizer Stock: Which to Buy as Omicron Spreads?
  1,103 评论
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4099386477789900","uuid":"4099386477789900","gmtCreate":1636283411305,"gmtModify":1637170987700,"name":"ZenS","pinyin":"zens","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/324509a48d68e3dda5197e34410bd081","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":106,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":8,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":606690213,"gmtCreate":1638867846736,"gmtModify":1638867846828,"author":{"id":"4099386477789900","authorId":"4099386477789900","name":"ZenS","avatar":"https://static.tigerbbs.com/324509a48d68e3dda5197e34410bd081","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099386477789900","authorIdStr":"4099386477789900"},"themes":[],"htmlText":"[Happy]&nbsp;[Happy]&nbsp;","listText":"[Happy]&nbsp;[Happy]&nbsp;","text":"[Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606690213","repostId":"1153880755","repostType":4,"repost":{"id":"1153880755","kind":"news","pubTimestamp":1638867395,"share":"https://ttm.financial/m/news/1153880755?lang=&edition=full","pubTime":"2021-12-07 16:56","market":"us","language":"en","title":"4 of the Safest Dividend Stocks That'll Help You Crush Inflation","url":"https://stock-news.laohu8.com/highlight/detail?id=1153880755","media":"Motley Fool","summary":"Apple and four other tech stalwarts are well insulated from inflation.","content":"<p>Rising inflation is wreaking havoc on many high-growth stocks as investors fret over higher costs and reduced future valuations. Higher interest rates, which counter inflation, are also sparking fears of an economic slowdown and causing investors to rotate from dividend stocks toward lower-risk bonds.</p>\n<p>Faced with&nbsp;these challenges, it might seem like a bad idea to buy dividend-paying tech stocks. However, these four tech dividend stocks should remain resilient and easily withstand the upcoming inflation-related challenges.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3710057a11169b9e18f5bf46888ca7fb\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>Image source: Apple.</span></p>\n<p><b>1. Apple</b></p>\n<p><b>Apple</b>&nbsp;only pays a forward dividend yield of 0.5%, but its lowpayout ratioof 15% indicates there's still plenty of room for much higher payments. Apple's stock price has risen nearly 270% over the past three years, but it still doesn't look terribly expensive at 29 times forward earnings.</p>\n<p>Apple is an inflation-resistant company for two simple reasons. First, it has the clout to negotiate more favorable prices from its suppliers. Second, it probably won't lose a lot of its loyal customers if it charges higher prices for its hardware since they're already firmly locked into its software ecosystem.</p>\n<p>Apple has also consistently executed big stock buybacks, which have reduced its outstanding shares by nearly 22% over the past five years. Spending more cash on those buybacks, which boosts the value of its remaining shares, is a better strategy than letting its cash stagnate in an inflationary environment.</p>\n<p>Apple will face a&nbsp;near-term slowdown&nbsp;as it grapples with supply chain constraints, but its long-term outlook is still bright. Its services ecosystem continues to expand, and it will eventually expand into new next-gen markets like augmented reality, virtual reality, and connected cars.</p>\n<p><b>2. Verizon</b></p>\n<p><b>Verizon</b>&nbsp;pays a forward dividend yield of 5%. The telecom giant has raised that dividend annually for 15 straight years, and it's spent less than half of its earnings per share on those payments over the past 12 months. The stock also trades at just nine times forward earnings.</p>\n<p>At first glance, Verizon seems like a lackluster investment. It's declined more than 10% over the past three years as the&nbsp;<b>S&amp;P 500</b>&nbsp;has risen nearly 70%.</p>\n<p>However, Verizon's stock will likely remain stable as rising inflation and higher interest rates rattle the markets. As the largest wireless carrier in the U.S., Verizon can likely pass on most of its higher costs onto consumers without significantly increasing its churn rates. It's also a more streamlined company than&nbsp;<b>AT&amp;T</b>, which is still trying toundo the damageof the debt-fueled expansions of its media and pay-TV ecosystems.</p>\n<p>Verizon's stable returns, sticky ecosystem, high dividend, and low valuation will all make it an ideal safe-haven stock in an inflationary market.</p>\n<p><b>3. Qualcomm</b></p>\n<p><b>Qualcomm</b>, one of the world's largest mobile chipmakers, pays a forward dividend yield of 1.5%. It's raised its annual payout over the past two years, and it's only spent about a third of its earnings on its dividends over the past 12 months.</p>\n<p>Qualcomm's two main businesses are both well-insulated from inflation. Its Snapdragon system on chips (SoCs), which bundle together a mobile CPU, GPU, and baseband modem, power most of the world's high-end smartphones. They can also be found in&nbsp;virtual reality headsets, cars, and drones. The secular growth of those markets will give Qualcomm plenty of pricing power.</p>\n<p>Its licensing business, which leverages its portfolio of wireless patents to earn a cut of every smartphone sold worldwide, also generates a stable stream of high-margin revenue. It then plows a large portion of that excess cash into big buybacks and dividends.</p>\n<p>Qualcomm's stock has already risen more than 200% as investors have recognized those long-term strengths, but it still looks cheap at 17 times forward earnings.</p>\n<p><b>4. Texas Instruments</b></p>\n<p><b>Texas Instruments</b>&nbsp;manufactures a wide range of analog and embedded chips for consumer electronics, cars, industrial machines, and other markets. These chips aren't as powerful as Qualcomm's mobile chips, but they're just as essential and less capital-intensive to produce.</p>\n<p>Unlike Qualcomm, which outsources the production of its chips to third-party foundries, TI manufactures its own chips in-house. That business model insulates it from the ongoing chip shortage, and its cost-cutting migration from 200mm to 300mm wafers over the past few years enabled it to significantly reduce its own manufacturing costs and boost its gross margins.</p>\n<p>TI's business is naturally resistant to inflation since it has much better control over its own supply chain and operating expenses than other chipmakers, and it generates plenty of excess cash for buybacks and dividends. It reduced its number of outstanding shares by 46% between 2004 and 2020, and it's raised its dividend annually for 18 straight years. It currently pays a forward dividend yield of 2.4%, which is supported by a sustainable payout ratio of 52%.</p>\n<p>TI's stock has more than doubled over the past three years, but it still trades at 23 times forward earnings. That reasonable valuation, along with its healthy yield and stable business, makes TI a reliable and inflation-resistant tech stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 of the Safest Dividend Stocks That'll Help You Crush Inflation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 of the Safest Dividend Stocks That'll Help You Crush Inflation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-07 16:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/06/safe-dividend-stocks-that-help-crush-inflation/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rising inflation is wreaking havoc on many high-growth stocks as investors fret over higher costs and reduced future valuations. Higher interest rates, which counter inflation, are also sparking fears...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/06/safe-dividend-stocks-that-help-crush-inflation/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果","QCOM":"高通","TXN":"德州仪器","VZ":"Verizon Comms"},"source_url":"https://www.fool.com/investing/2021/12/06/safe-dividend-stocks-that-help-crush-inflation/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153880755","content_text":"Rising inflation is wreaking havoc on many high-growth stocks as investors fret over higher costs and reduced future valuations. Higher interest rates, which counter inflation, are also sparking fears of an economic slowdown and causing investors to rotate from dividend stocks toward lower-risk bonds.\nFaced with these challenges, it might seem like a bad idea to buy dividend-paying tech stocks. However, these four tech dividend stocks should remain resilient and easily withstand the upcoming inflation-related challenges.\nImage source: Apple.\n1. Apple\nApple only pays a forward dividend yield of 0.5%, but its lowpayout ratioof 15% indicates there's still plenty of room for much higher payments. Apple's stock price has risen nearly 270% over the past three years, but it still doesn't look terribly expensive at 29 times forward earnings.\nApple is an inflation-resistant company for two simple reasons. First, it has the clout to negotiate more favorable prices from its suppliers. Second, it probably won't lose a lot of its loyal customers if it charges higher prices for its hardware since they're already firmly locked into its software ecosystem.\nApple has also consistently executed big stock buybacks, which have reduced its outstanding shares by nearly 22% over the past five years. Spending more cash on those buybacks, which boosts the value of its remaining shares, is a better strategy than letting its cash stagnate in an inflationary environment.\nApple will face a near-term slowdown as it grapples with supply chain constraints, but its long-term outlook is still bright. Its services ecosystem continues to expand, and it will eventually expand into new next-gen markets like augmented reality, virtual reality, and connected cars.\n2. Verizon\nVerizon pays a forward dividend yield of 5%. The telecom giant has raised that dividend annually for 15 straight years, and it's spent less than half of its earnings per share on those payments over the past 12 months. The stock also trades at just nine times forward earnings.\nAt first glance, Verizon seems like a lackluster investment. It's declined more than 10% over the past three years as the S&P 500 has risen nearly 70%.\nHowever, Verizon's stock will likely remain stable as rising inflation and higher interest rates rattle the markets. As the largest wireless carrier in the U.S., Verizon can likely pass on most of its higher costs onto consumers without significantly increasing its churn rates. It's also a more streamlined company than AT&T, which is still trying toundo the damageof the debt-fueled expansions of its media and pay-TV ecosystems.\nVerizon's stable returns, sticky ecosystem, high dividend, and low valuation will all make it an ideal safe-haven stock in an inflationary market.\n3. Qualcomm\nQualcomm, one of the world's largest mobile chipmakers, pays a forward dividend yield of 1.5%. It's raised its annual payout over the past two years, and it's only spent about a third of its earnings on its dividends over the past 12 months.\nQualcomm's two main businesses are both well-insulated from inflation. Its Snapdragon system on chips (SoCs), which bundle together a mobile CPU, GPU, and baseband modem, power most of the world's high-end smartphones. They can also be found in virtual reality headsets, cars, and drones. The secular growth of those markets will give Qualcomm plenty of pricing power.\nIts licensing business, which leverages its portfolio of wireless patents to earn a cut of every smartphone sold worldwide, also generates a stable stream of high-margin revenue. It then plows a large portion of that excess cash into big buybacks and dividends.\nQualcomm's stock has already risen more than 200% as investors have recognized those long-term strengths, but it still looks cheap at 17 times forward earnings.\n4. Texas Instruments\nTexas Instruments manufactures a wide range of analog and embedded chips for consumer electronics, cars, industrial machines, and other markets. These chips aren't as powerful as Qualcomm's mobile chips, but they're just as essential and less capital-intensive to produce.\nUnlike Qualcomm, which outsources the production of its chips to third-party foundries, TI manufactures its own chips in-house. That business model insulates it from the ongoing chip shortage, and its cost-cutting migration from 200mm to 300mm wafers over the past few years enabled it to significantly reduce its own manufacturing costs and boost its gross margins.\nTI's business is naturally resistant to inflation since it has much better control over its own supply chain and operating expenses than other chipmakers, and it generates plenty of excess cash for buybacks and dividends. It reduced its number of outstanding shares by 46% between 2004 and 2020, and it's raised its dividend annually for 18 straight years. It currently pays a forward dividend yield of 2.4%, which is supported by a sustainable payout ratio of 52%.\nTI's stock has more than doubled over the past three years, but it still trades at 23 times forward earnings. That reasonable valuation, along with its healthy yield and stable business, makes TI a reliable and inflation-resistant tech stock.","news_type":1,"symbols_score_info":{"AAPL":0.9,"QCOM":0.9,"TXN":0.9,"VZ":0.9}},"isVote":1,"tweetType":1,"viewCount":1563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603242331,"gmtCreate":1638418542071,"gmtModify":1638418542188,"author":{"id":"4099386477789900","authorId":"4099386477789900","name":"ZenS","avatar":"https://static.tigerbbs.com/324509a48d68e3dda5197e34410bd081","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4099386477789900","authorIdStr":"4099386477789900"},"themes":[],"htmlText":"Both","listText":"Both","text":"Both","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603242331","repostId":"1119742422","repostType":2,"repost":{"id":"1119742422","kind":"news","pubTimestamp":1638368504,"share":"https://ttm.financial/m/news/1119742422?lang=&edition=full","pubTime":"2021-12-01 22:21","market":"us","language":"en","title":"Moderna or Pfizer Stock: Which to Buy as Omicron Spreads?","url":"https://stock-news.laohu8.com/highlight/detail?id=1119742422","media":"TheStreet","summary":"Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks ","content":"<p>Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks are back in the spotlight. Today, we take a closer look at Moderna and Pfizer stocks.</p>\n<p>COVID-19 keeps haunting the markets. New variant Omicron has renewed fears worldwide about a new health and economic crisis, since little is still known about how this variant affects vaccinated and non-vaccinated people.</p>\n<p>The stock market sold off on Friday, November 26, after Omicron news hit the wire. The S&amp;P 500&nbsp;dropped 2% amid uncertainty. One of the few gainers was Moderna stock, which jumped 20% on Friday’s trading session, while Pfizer stock&nbsp;was up a more modest 2.5%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b55d87c377ec124bb84173bfb955b9fa\" tg-width=\"689\" tg-height=\"621\" width=\"100%\" height=\"auto\"><span>Figure 1: SPY, MRNA and PFE performance in the past 5-trading days.</span></p>\n<p>Between two of the main COVID-19 vaccine makers, we assess Moderna and Pfizer stocks and ask ourselves: which is a better buy as Omicron fear lingers?</p>\n<p><b>Wall Street is neutral on Moderna</b></p>\n<p>Moderna stock currently has a hold consensus among 13 analysts and an average price target of $298, which suggests 17% downside from current levels. Wall Street’s assessment suggests that the stock price may have moved ahead of fundamentals, as MRNA has gained more than 1,200% since the COVID-19 pandemic started.</p>\n<p>The most recent report on Moderna stock came from Piper Sandler’s Edward Tenthoff, who&nbsp;reiterated&nbsp;his buy recommendation and forecasted a $348 price target on the back of Omicron news. The analyst sees the company prepared for the emergence of new variants and \"ideally suited to rapidly swap in new versions of the Spike antigen\" to make new COVID-19 vaccines.</p>\n<p>Morgan Stanley’s Matthew Harrison&nbsp;reiterated&nbsp;his neutral rating on MRNA a week ago with a $313 price target. The analyst mentioned that the announcement of Moderna’s flu vaccine data before year-end could be a positive catalyst for the stock. If the results are positive, the market could price in about $10 billion in long-term flu and COVID vaccine revenue, bumping shares by 10%.</p>\n<p><b>Pfizer: moderate buy, but experts are skeptical</b></p>\n<p>Wall Street is currently bullish on Pfizer, based on stock ratings. However, average price target consensus suggests that valuations could be stretched thin, following the November rally. PFE has a moderate buy recommendation based on 13 reports and a $50 average price target.</p>\n<p>JPMorgan‘s Chris Schott&nbsp;raised&nbsp;the firm's price target on Pfizer to $53 from $42 and kept a neutral rating. Covid remains a focal point of the Pfizer story, and Comirnaty and Paxlovid sales are \"set to clearly exceed expectations”. While the analyst sees limited upside from the company's core business, he would not be surprised to see shares rally in the near-term on omicron headlines.</p>\n<p>The most recent update on PFE came from Mizuho Securities’ Vamil Divan. He is&nbsp;skeptical&nbsp;on Pfizer stock and sees 16% downside risk. But according to the analyst, Omicron may increase near-term demand for Pfizer’s COVID-19 vaccine, especially for booster doses.</p>\n<p><b>Wall Street Memes’ take</b></p>\n<p>COVID-19 vaccine makers may naturally benefit in the near-term from Omicron fears. Moderna, for instance, has risen more than 1,200% since the beginning of the COVID-19 pandemic in March 2020, while Pfizer stock has climbed 79% during the same period.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/198c43532bf2d097bc94e078b539a044\" tg-width=\"684\" tg-height=\"577\" width=\"100%\" height=\"auto\"><span>Figure 2: MRNA and PFE performance in the past 5-years.</span></p>\n<p>Pfizer is much larger than Moderna, with a market cap size of $300 billion compared to Moderna’s $133 billion. Both companies have strong vaccine pipelines and technology, but Moderna likely benefits from the current pandemic for being more of a pure-play stock.</p>\n<p>Due to business model diversification, we see MRNA as a better short-term bet on COVID-19 developments. However, for this same reason and due to richer 2023 P/E of 32x, the stock is likely to be more volatile and present higher downside risk. PFE, on the other hand, could be a better long-term bet on healthcare at large, especially considering de-risked 2023 P/E of only 13x.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna or Pfizer Stock: Which to Buy as Omicron Spreads? </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna or Pfizer Stock: Which to Buy as Omicron Spreads? \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-01 22:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/reddit-trends/moderna-or-pfizer-stock-which-to-buy-as-omicron-spreads><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks are back in the spotlight. Today, we take a closer look at Moderna and Pfizer stocks.\nCOVID-19 keeps...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/reddit-trends/moderna-or-pfizer-stock-which-to-buy-as-omicron-spreads\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.thestreet.com/memestocks/reddit-trends/moderna-or-pfizer-stock-which-to-buy-as-omicron-spreads","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119742422","content_text":"Pandemic fears have returned since the discovery of the Omicron variant, and vaccine-related stocks are back in the spotlight. Today, we take a closer look at Moderna and Pfizer stocks.\nCOVID-19 keeps haunting the markets. New variant Omicron has renewed fears worldwide about a new health and economic crisis, since little is still known about how this variant affects vaccinated and non-vaccinated people.\nThe stock market sold off on Friday, November 26, after Omicron news hit the wire. The S&P 500 dropped 2% amid uncertainty. One of the few gainers was Moderna stock, which jumped 20% on Friday’s trading session, while Pfizer stock was up a more modest 2.5%.\nFigure 1: SPY, MRNA and PFE performance in the past 5-trading days.\nBetween two of the main COVID-19 vaccine makers, we assess Moderna and Pfizer stocks and ask ourselves: which is a better buy as Omicron fear lingers?\nWall Street is neutral on Moderna\nModerna stock currently has a hold consensus among 13 analysts and an average price target of $298, which suggests 17% downside from current levels. Wall Street’s assessment suggests that the stock price may have moved ahead of fundamentals, as MRNA has gained more than 1,200% since the COVID-19 pandemic started.\nThe most recent report on Moderna stock came from Piper Sandler’s Edward Tenthoff, who reiterated his buy recommendation and forecasted a $348 price target on the back of Omicron news. The analyst sees the company prepared for the emergence of new variants and \"ideally suited to rapidly swap in new versions of the Spike antigen\" to make new COVID-19 vaccines.\nMorgan Stanley’s Matthew Harrison reiterated his neutral rating on MRNA a week ago with a $313 price target. The analyst mentioned that the announcement of Moderna’s flu vaccine data before year-end could be a positive catalyst for the stock. If the results are positive, the market could price in about $10 billion in long-term flu and COVID vaccine revenue, bumping shares by 10%.\nPfizer: moderate buy, but experts are skeptical\nWall Street is currently bullish on Pfizer, based on stock ratings. However, average price target consensus suggests that valuations could be stretched thin, following the November rally. PFE has a moderate buy recommendation based on 13 reports and a $50 average price target.\nJPMorgan‘s Chris Schott raised the firm's price target on Pfizer to $53 from $42 and kept a neutral rating. Covid remains a focal point of the Pfizer story, and Comirnaty and Paxlovid sales are \"set to clearly exceed expectations”. While the analyst sees limited upside from the company's core business, he would not be surprised to see shares rally in the near-term on omicron headlines.\nThe most recent update on PFE came from Mizuho Securities’ Vamil Divan. He is skeptical on Pfizer stock and sees 16% downside risk. But according to the analyst, Omicron may increase near-term demand for Pfizer’s COVID-19 vaccine, especially for booster doses.\nWall Street Memes’ take\nCOVID-19 vaccine makers may naturally benefit in the near-term from Omicron fears. Moderna, for instance, has risen more than 1,200% since the beginning of the COVID-19 pandemic in March 2020, while Pfizer stock has climbed 79% during the same period.\nFigure 2: MRNA and PFE performance in the past 5-years.\nPfizer is much larger than Moderna, with a market cap size of $300 billion compared to Moderna’s $133 billion. Both companies have strong vaccine pipelines and technology, but Moderna likely benefits from the current pandemic for being more of a pure-play stock.\nDue to business model diversification, we see MRNA as a better short-term bet on COVID-19 developments. However, for this same reason and due to richer 2023 P/E of 32x, the stock is likely to be more volatile and present higher downside risk. PFE, on the other hand, could be a better long-term bet on healthcare at large, especially considering de-risked 2023 P/E of only 13x.","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1103,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}